Gencurix Inc
229000
Company Profile
Business description
Gencurix Inc develops diagnosis treatment kits. The company focuses on developing molecular diagnostic tests based on core technologies of liquid biopsy and biomarker discovery. It offers products including GenesWell BCT, a breast cancer test, GenesWell ddEGFR Mutation Test, Droplex, eDX, Geno CTC, and others.
Contact
243 Digital-ro
15th floor, Jiha City
Guro-gu
Seoul
KORT: +82 7074329481
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
69
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,069.00 | 14.40 | -0.16% |
| CAC 40 | 8,103.58 | 0.27 | -0.00% |
| DAX 40 | 24,340.06 | 56.09 | 0.23% |
| Dow JONES (US) | 48,700.33 | 30.83 | -0.06% |
| FTSE 100 | 9,870.68 | 18.54 | -0.19% |
| HKSE | 25,818.93 | 44.79 | 0.17% |
| NASDAQ | 23,596.10 | 17.21 | -0.07% |
| Nikkei 225 | 50,750.39 | 342.60 | 0.68% |
| NZX 50 Index | 13,529.06 | 11.33 | 0.08% |
| S&P 500 | 6,932.17 | 0.12 | 0.00% |
| S&P/ASX 200 | 8,762.70 | 21.10 | -0.24% |
| SSE Composite Index | 3,940.95 | 20.97 | 0.53% |